Continue Apixaban Without Switching to Heparin or Enoxaparin
For a patient with atrial fibrillation on apixaban admitted for small bowel obstruction with an NG tube and no planned surgery, apixaban should be continued without switching to parenteral anticoagulation (heparin or enoxaparin). The FDA label explicitly states that apixaban can be administered via NG tube, and there is no indication for bridging therapy in this non-surgical scenario 1.
Rationale for Continuing Apixaban
Apixaban Administration via NG Tube is FDA-Approved
The apixaban drug label provides clear guidance: apixaban tablets may be crushed and suspended in 60 mL of water or D5W and promptly delivered through a nasogastric tube 1. Crushed apixaban tablets remain stable in water and D5W for up to 4 hours 1. This eliminates any concern about drug absorption through the NG tube.
No Indication for Bridging Therapy
Bridging anticoagulation with heparin or enoxaparin is NOT recommended in this scenario for several critical reasons:
Bridging is only indicated for perioperative management when anticoagulation must be interrupted 2, 3, 4, 5. The 2019 AHA/ACC/HRS guidelines and 2022 CHEST guidelines explicitly state that bridging therapy is reserved for patients requiring temporary interruption of anticoagulation for surgery or invasive procedures 4, 5.
The BRIDGE trial definitively showed that bridging anticoagulation in atrial fibrillation patients (without mechanical valves) increases bleeding risk without reducing thromboembolism 5. This landmark study found bridging was associated with significantly higher bleeding rates and no benefit in preventing stroke.
Current guidelines state: "Bridging anticoagulation during the 24 to 48 hours after stopping apixaban and prior to intervention is not generally required" 1. This applies when apixaban is stopped—in your case, there's no reason to stop it at all.
Small Bowel Obstruction Without Surgery Does Not Require Anticoagulation Changes
Since there is no current plan for surgery, this is a medical management scenario. The patient's anticoagulation should continue uninterrupted unless:
- Active pathological bleeding occurs 1
- Emergency surgery becomes necessary
- The patient develops contraindications to anticoagulation
Practical Management Algorithm
Step 1: Verify NG tube placement and function
Step 2: Crush apixaban tablets and suspend in 60 mL of water or D5W 1
Step 3: Administer promptly through NG tube (within 4 hours of preparation) 1
Step 4: Continue twice-daily dosing schedule
- If patient normally takes 5 mg twice daily, continue this dose
- If patient meets dose-reduction criteria (age ≥80, weight ≤60 kg, or creatinine ≥1.5 mg/dL with at least 2 of these factors), continue 2.5 mg twice daily 1
Step 5: Monitor for bleeding complications and resolution of SBO
Critical Pitfalls to Avoid
Do NOT switch to enoxaparin or heparin "just to be safe" - this actually increases bleeding risk without benefit 5. The BRIDGE trial showed bridging increases major bleeding from 1.3% to 3.2% (hazard ratio 3.09) without reducing stroke risk 5.
Do NOT hold apixaban doses unnecessarily - premature discontinuation increases stroke risk. The FDA label warns: "Premature discontinuation of any oral anticoagulant, including apixaban, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events" 1.
Do NOT assume oral medications cannot be given via NG tube - apixaban is specifically approved for NG administration 1.
When to Consider Changing Anticoagulation
You should only consider switching from apixaban if:
Surgery becomes planned: Hold apixaban 24-48 hours before procedure depending on bleeding risk 1. For high bleeding risk procedures, stop 48 hours prior; for low bleeding risk, stop 24 hours prior 6, 4.
Active major bleeding occurs: Discontinue immediately and consider reversal with andexanet alfa if life-threatening 5.
NG tube becomes non-functional and patient cannot swallow: Then consider temporary switch to parenteral anticoagulation until oral route is re-established.
Severe renal impairment develops (CrCl <30 mL/min): Apixaban is contraindicated in severe renal impairment 7, 8.
The evidence strongly supports continuing apixaban via NG tube in this medically managed SBO patient without surgery planned. Switching to parenteral anticoagulation would increase bleeding risk, add unnecessary complexity, and provide no clinical benefit.